FGEN FibroGen
- 1.160
- -0.060-4.92%
- 1.170
- +0.010+0.86%
FibroGen News
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of
FibroGen Shares Climb On Strong Q1 Sales
FibroGen, Inc. (NASDAQ:FGEN) shares are trading higher Tuesday after the company posted mixed first-quarter financial results. Here's a look at the key figures from the report. The Details:FibroGen re
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply during Tuesday's session following upbeat quarterly ear
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Top Premarket Gainers
Esperion Therapeutics (ESPR) shares surged more than 25% Tuesday premarket after the company posted improved Q1 financial results. FibroGen (FGEN) shares rose nearly 20% after the company reported a n
FibroGen to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate in the following investor conferences: Bank of America He
Earnings Call Summary | FibroGen(FGEN.US) Q1 2024 Earnings Conference
The following is a summary of the FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript:Financial Performance:FibroGen recorded a Q1 2024 revenue of $55.9 million, a 55% increase from Q1 2023, driven
FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
Goldman Sachs Remains a Sell on FibroGen (FGEN)
FibroGen Shares Are Trading Higher After the Company Reported Mixed Q1 Financial Results.
FibroGen Shares Are Trading Higher After the Company Reported Mixed Q1 Financial Results.
FibroGen Q1 2024 GAAP EPS $(0.33) Misses $(0.31) Estimate, Sales $55.902M Beat $36.666M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 59.26 percent increase over losses of $(0.81) pe
FibroGen | 10-Q: Quarterly report
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, Vs. Street Est of $36.4M
04:11 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M
FibroGen 1Q Rev $55.9M >FGEN
FibroGen 1Q Rev $55.9M >FGEN
Catalyst Watch: Disney Earnings, Apple iPad Event and Fed Speakers Back on the Circuit
FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4
FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4
FibroGen Announces Clinical Data From Dose Escalation Phase 1b Study of FG-3246 (FOR46) In...
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Analysis
Price Target
No Data
